Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

PROSTATE CANCER

AVPR1A: a target in CRPC?

Nature Reviews Urology volume 16, page 508 (2019)Cite this article

Subjects

Access through your institution
Buy or subscribe

Drugs targeting the arginine vasopressin receptor 1A (AVPR1A) could be repurposed for use in patients with castration-resistant prostate cancer (CRPC), according to a study in Science Translational Medicine.

Gene expression profiling of CRPC cells has identified AVPR1A as a dual target gene of androgen receptor variant 7 (AR-V7), which is constitutively active and acts as a potential driver of resistance, and its coactivator VAV3. AVPR1A copy number amplification is often observed in CRPC, and AVPR1A mRNA is increased in advanced prostate cancer compared with primary disease. AVPR1A targeting could, therefore, be a therapeutic option; an AVPR1A antagonist, relcovaptan, has been shown to be safe and efficacious in clinical trials for various disorders.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • Zhao, N. et al. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Sci. Transl Med. 11, eaaw4636 (2019)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Urology http://www.nature.com/nrurol/

    Annette Fenner

Authors
  1. Annette Fenner
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Annette Fenner.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fenner, A. AVPR1A: a target in CRPC?. Nat Rev Urol 16, 508 (2019). https://doi.org/10.1038/s41585-019-0218-y

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41585-019-0218-y

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer